No surrender: A group of marquee biotech players bets on the $350M PhIII resurrection story of a heavyweight contender - Endpoints News

Anyone reading Biogen’s press release on the flat failure of dexpramipexole in treating ALS couldn’t overlook the note of finality then R&D chief Doug Williams used to mark its grave 10 years ago. The drug failed the primary endpoint. Follow-up analysis left …

A nine-figure raise is a lot of money for private biotechs, and something that many are eager to publicize. But one startup is keeping its mouth almost completely shut about a new funding round, inst… [+386 chars]

full article...